Mon, 08 Dec 2025

Grover Norquist, President of Americans for Tax Reform, explains how “Most Favored Nation” drug pricing is effectively the importing of counterproductive foreign nation price controls, how the policy would raise the cost of new inventions, and how increased fees and/or taxes on patents run counter to the Trump administration’s pro-growth agenda.
























